Form 4 for ABBV AbbVie
Accepted 2026-02-27 00:00:00 ET · period of report 2026-02-25 · accession 0001951400-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-27 | 2026-02-25 | ABBV | Siatis Perry C | EVP, GC AND Sec | M - OptEx | $172.62 | +22.4K | 53.2K | +73% | +$3.86M |
| D | 2026-02-27 | 2026-02-25 | ABBV | Siatis Perry C | EVP, GC AND Sec | S - Sale+OE | $230.00 | -22.4K | 38.1K | -37% | -$5.15M |
| DM | 2026-02-27 | 2026-02-25 | ABBV | Siatis Perry C | EVP, GC AND Sec | M - OptEx | $172.62 | -22.4K | 14.6K | -61% | -$3.86M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2026-02-25 | M | A | 7,292 | $192.86 | 60,518 | D | — | — | |
| 2 | Common | Common Stock, $0.01 par value | 2026-02-25 | M | A | 7,314 | $149.62 | 45,451 | D | — | — | |
| 3 | Common | Common Stock, $0.01 par value | 2026-02-25 | M | A | 7,775 | $175.28 | 53,226 | D | — | — | |
| 4 | Common | Common Stock, $0.01 par value | 2026-02-25 | S | D | 22,381 | $230.00 | 38,137 | D | — | — | |
| 5 | Derivative | Option (Right to buy) | 2026-02-25 | M | D | 7,314 | $149.62 | 0 | D | $149.62 · — to 2033-02-15 | 7,314 Common Stock | (F1) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026. |
| 6 | Derivative | Option (Right to buy) | 2026-02-25 | M | D | 7,775 | $175.28 | 7,774 | D | $175.28 · — to 2034-02-14 | 7,775 Common Stock | (F2) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027. |
| 7 | Derivative | Option (Right to buy) | 2026-02-25 | M | D | 7,292 | $192.86 | 14,583 | D | $192.86 · — to 2035-02-12 | 7,292 Common Stock | (F3) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,292 shares on February 13, 2026 and becomes exercisable in annual increments of 7,292 on February 13, 2027, and 7,291 on February 13, 2028. |